<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04181710</url>
  </required_header>
  <id_info>
    <org_study_id>OXYOP 2 (29BRC19.0048)</org_study_id>
    <nct_id>NCT04181710</nct_id>
  </id_info>
  <brief_title>Evaluation of a Marine OXYgen Carrier for Organ Preservation</brief_title>
  <acronym>OXYOP 2</acronym>
  <official_title>Evaluation of a Marine OXYgen Carrier for Organ Preservation : a Multicenter Randomized Study Evaluating the Efficacy of HEMO2life® Versus Standard of Care in Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preventing ischemia/reperfusion injuries (IRIs) is a major issue in kidney transplantation,
      particularly for transplant recipients receiving a kidney from extended criteria donors
      (ECD). The main consequence of IRIs is delayed graft function (DGF).

      The medical device HEMO2life®, an oxygen carrier developed by the Hemarina French Company, is
      a natural extracellular hemoglobin (Hb) isolated from the marine lugworm Arenicola marina.
      This biopolymer of high molecular weight (~3,600 kDa) has a large oxygen binding capacity,
      carrying up to 156 oxygen molecules when saturated (4 for human Hb). It releases oxygen
      according to a simple gradient and exhibits an intrinsic superoxide dismutase-like activity
      preventing both the occurrence of potentially harmful heme-protein-associated free radical
      species and the release of Hb degradation products.

      Recently a safety study in 60 renal grafts using HEMO2life® as additive to organ preservation
      solution (Oxyop study, NCT02652520) was completed, that confirmed that the use of HEMO2life®
      is safe for patients and grafts.

      In the Oxyop study, even if the protocol was not designed to show a benefit of the use of
      HEMO2life®, significantly less delayed graft function (DGF) and a shorter renal function
      recovery was observed.

      The present research focuses on the efficacy of HEMO2life®, which is an oxygen carrier added
      in preservation solution in kidney transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of HEMO2life® as an additive to standard organ preservation solution to prevent delayed graft function following renal transplantation.</measure>
    <time_frame>From day 0 to day 7</time_frame>
    <description>Delayed graft function defined as the requirement for dialysis during the first week after transplantation will be compared as per the confirmatory testing strategy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess and compare graft and patient survival in the two groups.</measure>
    <time_frame>From month 0 to month 12</time_frame>
    <description>Graft and patient survival at one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of HEMO2life® on renal parameters compared with standard of care</measure>
    <time_frame>From month 0 to month 12</time_frame>
    <description>Evaluation using DGF assessed with alternative definitions: more than one dialysis session, need for dialysis except for hyperkaliemia or overhydration reason, time to reach a creatinine value of 250 µmol/l, DGF duration and using Renal function (creatinine value and eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in specific populations depending on type of donors and the type of preservation solution.</measure>
    <time_frame>From month 0 to month 12</time_frame>
    <description>Rate of primary non function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of HEMO2Life® on the degree and progression of interstitial fibrosis on the pre-implantation and 3 month biopsies</measure>
    <time_frame>biopsies pre-implantation and month 3</time_frame>
    <description>Rate of biopsy-proven acute rejection at one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of HEMO2life® on quality of life following renal transplant at Month-1, 3 and 12.</measure>
    <time_frame>From Day 0 to month 12</time_frame>
    <description>Quality of life assess using the generic self-administered questionnaire EuroQol-5 Dimensions (EQ-5D) and a specific questionnaire for renal transplant recipients in the French language: the ReTransQol (RTQ) [0-100]. For RTQ, higher score mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of HEMO2life® post transplant</measure>
    <time_frame>From organ preservation to month 12</time_frame>
    <description>Safety profile of HEMO2life® post transplant based on 3 analysis : graft safety, recipient safety, graft function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>End Stage Renal Diseases</condition>
  <arm_group>
    <arm_group_label>HEMO2life</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HEMO2life® will be used for ex vivo graft preservation at the dose of 1g per liter of preservation solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Organ preserved in preservation solution routinely used according to the local practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Kidney transplant</intervention_name>
    <description>Organ preserved in preservation solution</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>HEMO2life</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Kidney graft:

          -  Any pair of kidneys retrieved in an adult donor in one of first line participating
             centers.

          -  Any pair of kidneys from a deceased donor after brain or cardiac death

          -  For Patient:

          -  Male or female renal allograft recipients at least 18 years old

          -  Patient who signed an inform consent form

          -  Patient receiving one graft from an included pair of kidneys

        Exclusion criteria :

          -  For kidney :

          -  Graft from a living donor

          -  Graft dedicated to a multi-organ transplantation or dual kidney transplantation,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yannick LE MEUR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator and Nephrology coordinator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benoit BARROU</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urology coordinator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yannick LE MEUR</last_name>
    <phone>02.98.34.70.14</phone>
    <email>yannick.lemeur@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christelle RATAJACZAK</last_name>
    <phone>02.98.34.70.61</phone>
    <email>christelle.ratajczak@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coralie POULAIN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnès DUVEAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamal BAMOULID</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre MERVILLE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick LE MEUR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas BOUVIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Elisabeth HENG</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane MOUSSON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel ROSTAING</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc HAZZAN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe REROLLE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel BADET</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie MOAL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moglie LE QUINTREC</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc FRIMAT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques DANTAL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laëtitia ALBANO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP Bicêtre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edouard LEFEVRE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP Henri Mondor</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe ATIAS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe LEGENDRE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis GLOTZ</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Association Hopital Foch</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud SNANOUDJ</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris La Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit BARROU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry ANTOINE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte COLOSIO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Léonard GOLBIN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle ETIENNE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Réunion</name>
      <address>
        <city>Saint-Denis</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri VACHER-COPONAT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume CLAISSE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie CAILLARD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nassim KAMAR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias BUCHLER</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney transplantation</keyword>
  <keyword>Organ preservation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning three years and ending fifteen years following the final study report completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

